IP Library Granted Patent US 9,662,342
Granted Patent B2
US 9,662,342 · App. 14/702,320 · Granted May 30, 2017

Formulations of cyclophosphamide liquid concentrate

Inventors: Nagesh R. Palepu (Southampton, PA); Philip Christopher Buxton (Great Dunmow, GB)
Assignee: AUROMEDICS PHARMA LLC
A61K31/664A61K9/0019A61K9/08A61K31/675A61K47/10A61K47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,662,342
App. No.
14/702,320
Granted
May 30, 2017
Kind
B2
Abstract

Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C.

Claims (27)

1. A cyclophosphamide containing, substantially non-aqueous liquid composition having extended stability, comprising:

a) about 100 to about 600 mg/ml of cyclophosphamide;

b) an ethanolic solvent system consisting of ethanol; and

c) an ethanol soluble acidifying agent;

wherein the cyclophosphamide and the ethanol soluble acidifying agent are solubilized in the ethanol and wherein the cyclophosphamide is the only pharmaceutically active ingredient.

2. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 1 , wherein the ethanol soluble acidifying agent is an organic or inorganic acid.

3. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 2 , wherein the ethanol-soluble acidifying agent is citric acid or anhydrous citric acid.

4. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 1 , wherein concentration of the cyclophosphamide is from about 200 to about 550 mg/ml.

5. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 4 , wherein concentration of the cyclophosphamide is about 200 or about 400 mg/ml.

6. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 1 , wherein said cyclophosphamide is cyclophosphamide monohydrate.

7. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 3 , wherein the citric acid is present in an amount of from about 0.2 to about 2.0% W/V.

8. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 7 , wherein the citric acid is present in an amount of from about 0.4 to about 0.8% % W/V.

9. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 8 , wherein the citric acid is present in an amount of from about 0.4 to about 0.6% % W/V.

10. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 1 , further comprising a source of chloride ions.

11. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 1 , further comprising an anti-oxidizing agent.

12. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 11 , wherein the anti-oxidizing agent is selected from the group consisting of thioglycerol, propyl gallate, methionine, cysteine and combinations thereof.

13. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 12 , wherein the anti-oxidizing agent is thioglycerol.

14. A cyclophosphamide containing, substantially non-aqueous liquid composition according to claim 1 , wherein the solution maintains at least about 95% cyclophosphamide content after about 18 months at a temperature of about 5° C.

15. A cyclophosphamide containing, substantially non-aqueous liquid composition according to claim 5 , wherein the solution maintains at least about 97% cyclophosphamide content after about 18 months at a temperature of about 5° C.

16. A cyclophosphamide containing, substantially non-aqueous liquid composition, consisting essentially of:

a) cyclophosphamide;

b) a solvent consisting of ethanol; and

c) citric acid;

wherein the cyclophosphamide and the citric acid are solubilized in the ethanol and wherein the cyclophosphamide is the only pharmaceutically active ingredient.

17. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 16 , wherein the citric acid is anhydrous and the cyclophosphamide is cyclophosphamide monohydrate.

18. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 16 , wherein the ratio of cyclophosphamide to citric acid is 50:1.

19. The cyclophosphamide containing, substantially non-aqueous liquid composition of claim 18 , wherein the concentration of cyclophosphamide in the composition is either about 200 or about 400 mg/ml.

Assignments (3)
CHANGE OF NAME Recorded Jun 28, 2023
From: AUROMEDICS PHARMA LLC
To: EUGIA US LLC
Reel/Frame 064149/0826 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2015
From: PALEPU, NAGESH R.; BUXTON, PHILIP C.
To: SCIDOSE, LLC
Reel/Frame 035549/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2015
From: SCIDOSE, LLC
To: AUROMEDICS PHARMA LLC
Reel/Frame 035549/0760 →
Continuity (2)
Provisional Application 61991247 · May 9, 2014
Related Publication 20150320775A1 · Nov 12, 2015